Business Context and Reporting Period
Company: Lexicon Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 3, 2025
Context: The filing addresses a listing deficiency regarding the minimum bid price requirement for the company's common stock on The Nasdaq Stock Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
- Listing Status Change: The company applied to transfer its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market.
- Transfer Approval: Nasdaq approved the transfer, effective at the opening of business on July 7, 2025.
- Compliance Extension: The company received an additional 180-calendar day period (until December 30, 2025) to regain compliance with the minimum $1.00 bid price requirement.
Outlook, Risks, and Management Commentary
Compliance Requirements: To regain compliance, the closing bid price of the common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the extended period.
Contingencies: Eligibility for the additional period is subject to meeting the market value of publicly held shares requirement and other initial listing requirements for the Capital Market. The company has provided written notice of its intent to cure the deficiency by effecting a reverse stock split if necessary.
Risks: Failure to meet the bid price requirement or other listing standards by December 30, 2025, could result in delisting.
Investor Verification Checklist
- Verify the stock ticker symbol (LXRX) and confirm the trading venue change to the Nasdaq Capital Market on July 7, 2025.
- Monitor the daily closing bid price to track progress toward the $1.00 threshold for ten consecutive business days.
- Watch for future announcements regarding a potential reverse stock split if the bid price does not recover naturally.
- Confirm the company's continued compliance with the market value of publicly held shares requirement.